deferasirox spirig hc 360 mg compresse rivestite con film
spirig healthcare ag - deferasiroxum - compresse rivestite con film - deferasiroxum 360 mg, crospovidonum, cellulosum microcristallinum, poloxamerum 188, povidonum k 30, magnesii stearas, silica colloidalis anhydrica, Überzug: hypromellosum, macrogolum 4000, talcum, e 132, e 171 pro compresso obducto. - trattamento della transfusionsbedingten hämosiderose. trattamento cronico sovraccarico di ferro, una chelattherapie richiede, in pazienti con non-transfusionsabhängiger talassemia, a partire dai 10 anni. - synthetika
deferasirox teva
teva b.v. - deferasirox - deferasirox
deferasirox eg
eg s.p.a. - deferasirox - deferasirox
deferasirox doc
doc generici srl - deferasirox - deferasirox
deferasirox sandoz
sandoz s.p.a. - deferasirox - deferasirox
deferasirox aurobindo
aurobindo pharma (italia) s.r.l. - deferasirox - deferasirox
deferasirox abdi
abdi farma gmbh - deferasirox - deferasirox
deferasirox sun
sun pharmaceutical industries (europe) b.v. - deferasirox - deferasirox
deferasirox glenmark
glenmark arzneimittel gmbh - deferasirox - deferasirox
exjade 125 mg dispergierbare compresse
novartis pharma schweiz ag - deferasiroxum - dispergierbare compresse - deferasiroxum 125 mg, crospovidonum, lactosum monohydricum 135.9 mg, cellulosum microcristallinum, povidonum k 30, natrii laurilsulfas, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.170 mg. - trattamento della transfusionsbedingten hämosiderose.; trattamento cronico sovraccarico di ferro, una chelattherapie richiede, in pazienti con non-transfusionsabhängiger talassemia, a partire dai 10 anni. - synthetika